Press Releases

VYNE Therapeutics Announces Covered Status for ZILXI™ (minocycline) with Express Scripts

October, 07 2020

BRIDGEWATER, N.J., Oct. 07, 2020 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced a coverage update for its novel ZILXI™ (minocycline) topical foam, 1.5%. ZILXI is the first minocycline product of any form to be FDA approved for use in rosacea for the treatment of inflammatory lesions in adults and is just recently available in pharmacies nationwide. Express Scripts, one of the nation’s leading pharmacy benefit managers (PBMs), has elected to cover ZILXI effective October 2, 2020 on Express Scripts’ National Preferred, Flex, and Basic commercial formularies, representing millions of additional covered lives in the…

Read More

VYNE Therapeutics Announces ZILXI™ (minocycline) topical foam, 1.5% is Available in Pharmacies Nationwide Today, October 1st

October, 01 2020

ZILXI is the First FDA Approved Minocycline Product for the Treatment of Inflammatory Lesions of Rosacea in Adults ZILXI Offers Efficacy with Low Systemic Absorption BRIDGEWATER, N.J., Oct. 01, 2020 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that its novel ZILXI™ (minocycline) topical foam, 1.5% is available as of today, October 1, 2020 by prescription for the treatment of inflammatory lesions of rosacea in adults. Approved by the U.S. Food and Drug Administration (FDA) in May 2020, ZILXI is the first minocycline product of any form to be approved by the FDA for…

Read More

VYNE Therapeutics to Host Physician Symposium on AMZEEQ® and ZILXI™

September, 23 2020

BRIDGEWATER, N.J., Sept. 23, 2020 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that the Company will host a physician symposium on AMZEEQ® and ZILXI™ on Thursday, October 1, 2020 from 12pm – 3pm ET. The webinar will feature presentations by Key Opinion Leaders (KOLs) Ted Lain, M.D. (Sanova Dermatology), Julian Moore, FAAD (Hollywood Dermatology) and Linda Stein Gold, M.D. (Henry Ford Health System), who will discuss the current treatment landscape and unmet medical needs in treating patients with acne vulgaris and rosacea. Drs. Lain and Moore will discuss their experiences treating acne patients with AMZEEQ® (minocycline) topical foam, 4%…

Read More

VYNE Therapeutics Announces the Appointment of Patrick G. LePore to its Board of Directors

September, 14 2020

BRIDGEWATER, N.J., Sept. 14, 2020 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that the Board of Directors of the Company appointed Mr. Patrick G. LePore to serve as a director of the Company, effective as of September 10, 2020. “We are delighted to welcome Pat to our Board. Pat brings extensive experience from a long and successful career as a senior level executive and board member for several highly regarded companies in the pharmaceutical sector,” said David Domzalski, President and Chief Executive Officer of VYNE. “As VYNE establishes itself as a commercial stage…

Read More

VYNE Therapeutics (formerly Menlo Therapeutics) to Present at the Cantor Fitzgerald and H.C. Wainwright Investment Conferences in September

September, 09 2020

BRIDGEWATER, N.J., Sept. 09, 2020 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that David Domzalski, Chief Executive Officer, will present at the upcoming H.C. Wainwright 22nd Annual Global Investment Conference and the Cantor Fitzgerald Virtual Global Healthcare Conference.

Read More

Menlo Therapeutics Announces Completion of Corporate Name Change to VYNE Therapeutics

September, 08 2020

Will commence trading under new Nasdaq Ticker “VYNE”, September 8, 2020 Company to ring Nasdaq Closing Bell at 4pm ET today BRIDGEWATER, N.J., Sept. 08, 2020 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today completed its previously announced corporate name change from Menlo Therapeutics Inc. to VYNE Therapeutics Inc. and the change of its ticker symbol from “MNLO” to “VYNE”.  The name and ticker symbol changes are effective as of the opening of trading today, September 8, 2020. In celebration of the corporate name change, David Domzalski, President and Chief Executive Officer, together with other…

Read More